Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003471740 | SCV004206501 | likely pathogenic | Aplastic anemia | 2022-05-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003626871 | SCV004402410 | pathogenic | Familial hemophagocytic lymphohistiocytosis 2 | 2023-06-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PRF1 protein in which other variant(s) (p.Thr435Met) have been determined to be pathogenic (PMID: 15728124, 18927437, 19487666, 25233452, 32542393). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with PRF1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Trp425*) in the PRF1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 131 amino acid(s) of the PRF1 protein. |